Squire Patton Boggs has advised ASX-listed medical technology company, Singular Health Group Ltd, on a series of transformative transactions and raisings that position the company for accelerated growth in the United States and beyond, including:
- Strategic Placement: advising on the strategic placement with a globally recognised US technology and blockchain leader, through a placement of a 5% stake in the Company to this professional investor;
- Capital Raising: successfully completing a single-tranche placement, with proceeds dedicated to accelerating US commercialisation, including sales and marketing efforts, the development of an initial Medical Artificial Intelligence (AI)-in-the-Cloud system, and supporting working capital needs;
- Follow-On Investment: a follow-on investment by its largest shareholder, Marin & Sons; and
- Strategic Partnership and Placement: its memorandum of understanding and strategic placement with Provider Network Solutions for the commercial pilot and rollout of Singular's 3DICOM software.
Ashley Rose, Corporate partner in the firm’s Sydney office, advised Singular Health on these transactions. He has been supported by senior associate, Mitchell Coote and associates, Sarah Roper and Georgia Mateer.
Ashley Rose said: "We are delighted to have supported Singular Health on this series of transformative transactions. These initiatives not only strengthen Singular Health’s position as a leader in medical innovation but mark an exciting new chapter for their expansion in the US. It has been a privilege to work alongside the Singular Health team during this pivotal phase of their growth journey.”
